Cochrane · systematic review · CD015048
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery
Bryant, A, Hiu, S, Kunonga, PT, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
13
No studies
1
Included studies
NR
No studies 1 · 7.1%Ungraded 0 · 0%Very low 7 · 50%Low 0 · 0%Moderate 6 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Small‐volume residual disease (SVRD) < 1 cm versus NMRD in PDS studies
Population: women with advanced EOC after PDS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival: Median length of Small‐volume residual disease (SVRD) < 1 cm vs NMRD | HR 2.03 [1.8, 2.29] | 17 studies · 9404 participants | Moderate Downgraded: risk of bias |
Progression‐free survival: Median length of Small‐volume residual disease (SVRD) < 1 cm vs NMRD | HR 1.88 [1.63, 2.16] | 10 studies · 6596 participants | Moderate Downgraded: risk of bias |
Large‐volume residual disease (LVRD) > 1 cm versus no macroscopic residual disease (NMRD) in PDS studies
Population: women with advanced ovarian cancer after PDS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival: Median length of Large‐volume residual disease (LVRD) > 1 cm vs no macroscopic residual disease (NMRD) | HR 2.5 [2.13, 2.94] | 14 studies · 7988 participants | Moderate Downgraded: risk of bias |
Progression‐free survival: Median length of Large‐volume residual disease (LVRD) > 1 cm vs no macroscopic residual disease (NMRD) | HR 2.1 [1.84, 2.4] | 6 studies · 2629 participants | Moderate Downgraded: risk of bias |
Large‐volume residual disease (LVRD) > 1 cm versus small‐volume residual disease (SVRD) < 1 cm in PDS studies
Population: women with advanced EOC after PDS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival: Median length of Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm | HR 1.22 [1.13, 1.32] | 5 studies · 6000 participants | Moderate Downgraded: risk of bias |
Progression‐free survival: Median length of Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm | HR 1.3 [1.08, 1.56] | 2 studies · 3402 participants | Moderate Downgraded: risk of bias |
Small‐volume residual disease (SVRD) (< 1 cm) versus NMRD in IDS studies
Population: women with advanced EOC after primary IDS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival: Median length of Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD | HR 2.09 [1.2, 3.6] | 1 study · 310 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Progression‐free survival: Median length of Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD | no estimate extracted | 1 study · 322 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Large‐volume residual disease (LVRD) > 1 cm versus no macroscopic residual disease (NMRD) in IDS studies
Population: women with advanced EOC after primary IDS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival: Median length of Large‐volume residual disease (LVRD) > 1 cm vs no macroscopic residual disease (NMRD) | HR 2.23 [1.49, 3.34] | 1 study · 343 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Progression‐free survival Large‐volume residual disease (LVRD) > 1 cm vs no macroscopic residual disease (NMRD) | no estimate extracted | NR | No studies |
Large‐volume residual disease (LVRD) > 1 cm versus small‐volume residual disease (SVRD) < 1 cm in IDS studies
Population: women with advanced EOC after primary IDS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival: Median length of Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm | HR 1.6 [1.21, 2.11] | 6 studies · 1572 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Progression‐free survival: Median length of Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm | HR 1.76 [1.23, 2.52] | 4 studies · 1145 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Residual disease (RD) > 0 cm versus NMRD in IDS studies
Population: women with advanced EOC after primary IDS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival: Median length of Residual disease (RD) > 0 cm vs NMRD | HR 2.11 [1.35, 3.29] | 4 studies · 906 participants | Very low Downgraded: risk of bias, inconsistency, indirectness |
Progression‐free survival: Median length of Residual disease (RD) > 0 cm vs NMRD | HR 1.36 [1.05, 1.76] | 1 study · 471 participants | Very low Downgraded: risk of bias, inconsistency, indirectness |